The FDA on Thursday proposed a system to reduce potential conflicts of interest among members of its advisory committees on product approvals. The new rules, aimed at making the regulatory process more transparent, would require advisory board members to fill out a form disclosing any industry ties. If the FDA decides to allow them to sit anyway, the disclosure form would be posted on the agency's Web site.

Related Summaries